| 1 |
Green MD, Brenneman R, Powell SN, Bergom C. Harnessing the DNA Repair Pathway in Breast Cancer: Germline Mutations/Polymorphisms in Breast Radiation. Seminars in Radiation Oncology 2022;32:298-302. [DOI: 10.1016/j.semradonc.2022.01.011] [Reference Citation Analysis]
|
| 2 |
Huang A, Yao J, Liu T, Lin Z, Zhang S, Zhang T, Ma H. 53BP1 loss suppresses the radiosensitizing effect of icotinib hydrochloride in colorectal cancer cells. Int J Radiat Biol 2018;94:327-34. [PMID: 29388453 DOI: 10.1080/09553002.2018.1434322] [Reference Citation Analysis]
|
| 3 |
Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, Yang Q, Zhang T, Ma H. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol 2017;143:419-31. [PMID: 27838786 DOI: 10.1007/s00432-016-2302-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 4 |
Liu L, Jiao J, Wang Y, Zhang D, Wu J, Huang D. Lack of association of the TP53BP1 Glu353Asp polymorphism with risk of cancer: a systematic review and meta-analysis. PLoS One 2014;9:e90931. [PMID: 24603722 DOI: 10.1371/journal.pone.0090931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 5 |
Mehta MS, Dolfi SC, Bronfenbrener R, Bilal E, Chen C, Moore D, Lin Y, Rahim H, Aisner S, Kersellius RD, Teh J, Chen S, Toppmeyer DL, Medina DJ, Ganesan S, Vazquez A, Hirshfield KM. Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes. PLoS One 2013;8:e69851. [PMID: 23922822 DOI: 10.1371/journal.pone.0069851] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 6 |
Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, Shao C, Yang Q. 53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-κB through miR-146a. Carcinogenesis 2012;33:2593-600. [PMID: 23027628 DOI: 10.1093/carcin/bgs298] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 7 |
Borchiellini D, Etienne-grimaldi M, Thariat J, Milano G. The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treatment Reviews 2012;38:737-59. [DOI: 10.1016/j.ctrv.2012.02.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 8 |
Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, Schiff D, Moran MS, Golhar R, Chen C, Moore D, Ganesan S. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:e677-83. [PMID: 22520477 DOI: 10.1016/j.ijrobp.2012.01.089] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 9 |
Blitzblau R, Horton J. Evaluation of Single Nucleotide Polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS+RT). Breast Diseases: A Year Book Quarterly 2012;23:44-45. [DOI: 10.1016/j.breastdis.2012.01.001] [Reference Citation Analysis]
|
